U.S. patent application number 12/882027 was filed with the patent office on 2010-12-30 for mixed-cell gene therapy.
Invention is credited to Kwan Hee Lee, Moon Jong Noh, Sun Uk SONG, Youngsuk Yi.
Application Number | 20100330053 12/882027 |
Document ID | / |
Family ID | 28675569 |
Filed Date | 2010-12-30 |
![](/patent/app/20100330053/US20100330053A1-20101230-D00000.png)
![](/patent/app/20100330053/US20100330053A1-20101230-D00001.png)
![](/patent/app/20100330053/US20100330053A1-20101230-D00002.png)
![](/patent/app/20100330053/US20100330053A1-20101230-D00003.png)
![](/patent/app/20100330053/US20100330053A1-20101230-D00004.png)
![](/patent/app/20100330053/US20100330053A1-20101230-D00005.png)
![](/patent/app/20100330053/US20100330053A1-20101230-D00006.png)
![](/patent/app/20100330053/US20100330053A1-20101230-D00007.png)
![](/patent/app/20100330053/US20100330053A1-20101230-D00008.png)
United States Patent
Application |
20100330053 |
Kind Code |
A1 |
SONG; Sun Uk ; et
al. |
December 30, 2010 |
MIXED-CELL GENE THERAPY
Abstract
The subject invention is directed to a mixed cell composition to
generate a therapeutic protein at a target site by providing a
first population of mammalian cells transfected or transduced with
a gene that is sought to be expressed, and a second population of
mammalian cells that have not been transfected or transduced with
the gene, wherein endogenously existing forms of the second
population of mammalian cells are decreased at the target site, and
wherein generation of the therapeutic protein by the first
population of mammalian cells at the target site stimulates the
second population cells to induce a therapeutic effect.
Inventors: |
SONG; Sun Uk; (Inchon,
KR) ; Yi; Youngsuk; (Gaithersburg, MD) ; Lee;
Kwan Hee; (Gaithersburg, MD) ; Noh; Moon Jong;
(Gaithersburg, MD) |
Correspondence
Address: |
JHK Law
P.O. Box 1078
La Canada
CA
91012-1078
US
|
Family ID: |
28675569 |
Appl. No.: |
12/882027 |
Filed: |
September 14, 2010 |
Related U.S. Patent Documents
|
|
|
|
|
|
Application
Number |
Filing Date |
Patent Number |
|
|
11869640 |
Oct 9, 2007 |
|
|
|
12882027 |
|
|
|
|
11303547 |
Dec 16, 2005 |
7282200 |
|
|
11869640 |
|
|
|
|
10382137 |
Mar 5, 2003 |
7005127 |
|
|
11303547 |
|
|
|
|
60369162 |
Mar 29, 2002 |
|
|
|
Current U.S.
Class: |
424/93.21 |
Current CPC
Class: |
C12N 5/0656 20130101;
A61K 35/32 20130101; A61P 19/00 20180101; A61K 35/33 20130101; C12N
2501/155 20130101; C12N 2510/02 20130101; C12N 2502/99 20130101;
A61K 35/12 20130101; A61K 48/00 20130101; C12N 2502/13 20130101;
C12N 5/0655 20130101; C12N 2502/1317 20130101; C12N 2501/15
20130101; A61P 19/02 20180101; A61K 48/0008 20130101; A61P 43/00
20180101 |
Class at
Publication: |
424/93.21 |
International
Class: |
A61K 48/00 20060101
A61K048/00; A61P 19/02 20060101 A61P019/02; A61P 19/00 20060101
A61P019/00 |
Claims
1-18. (canceled)
19. A method of generating a therapeutic protein at a target site
in a mammal comprising: a) generating a recombinant vector
comprising a DNA sequence encoding the therapeutic protein
operatively linked to a promoter; b) transfecting or transducing a
population of cells in vitro with said recombinant vector; and c)
injecting a mixed cell composition comprising protein generating
effective amount of (i) a first population of cells transfected or
transduced with the gene; (ii) a second population of cells that
have not been transfected or transduced with the gene; and (iii) a
pharmaceutically acceptable carrier thereof, into the target site,
wherein endogenously existing forms of the second population of
mammalian cells are decreased at the target site, and wherein
generation of the therapeutic protein by the first population of
mammalian cells at the target site stimulates the second population
cells to induce a therapeutic effect.
20. The method according to claim 19, comprising a method of
generating hyaline cartilage in a mammal comprising: a) generating
a recombinant vector comprising a DNA sequence encoding
transforming growth factor .beta. (TGF-.beta.) or bone morphogenic
protein (BMP) operatively linked to a promoter; b) transfecting or
transducing a population of fibroblast or chondrocyte cells in
vitro with said recombinant vector; and c) injecting an injectable
mixed cell composition comprising hyaline cartilage-generating
effective amount of (i) a first population of fibroblast or
chondrocyte cells transfected or transduced with a gene encoding
TGF-.beta. or BMP; (ii) a second population of fibroblast or
chondrocyte cells that have not been transfected or transduced with
a gene encoding TGF-.beta. or BMP; and (iii) a pharmaceutically
acceptable carrier thereof, into a joint space of a mammal such
that expression of the DNA sequence encoding TGF-.beta. or BMP
within the joint space occurs resulting in the generation of
hyaline cartilage in the joint space.
21. The method according to claim 20, wherein said gene is
TGF-.beta.1, TGF-.beta.2, TGF-.beta.3, BMP-2, BMP-3, BMP-4, BMP-5,
BMP-6, or BMP-7.
22. The method according to claim 21, wherein said gene is
TGF-.beta.1 or BMP-2.
23. The method according to claim 20, wherein said ratio of the
second population of fibroblast or chondrocyte cells that have not
been transfected or transduced with a gene encoding TGF-.beta. or
BMP to the first population of fibroblast or chondrocyte cells that
have been transfected or transduced with a gene encoding TGF-.beta.
or BMP is from about 1-20 to 1.
24. The method according to claim 23, wherein said ratio is from
about 3-10 to 1.
25. The method according to claim 24, wherein said ratio is from
about 10 to 1.
26. The method according to claim 20, wherein the first population
of fibroblast or chondrocyte cells transfected or transduced with a
gene encoding TGF-.beta. or BMP is irradiated.
27. The method according to claim 20, wherein the first population
of fibroblast or chondrocyte cells transfected or transduced with
the gene encoding TGF-.beta. or BMP and the second population of
fibroblast or chondrocyte cells not transfected or transduced with
a gene encoding TGF-.beta. or BMP are syngeneic with respect to the
host recipient.
28. The method according to claim 20, wherein the first population
of fibroblast or chondrocyte cells transfected or transduced with
the gene encoding TGF-.beta. or BMP and the second population of
fibroblast or chondrocyte cells not transfected or transduced with
a gene encoding TGF-.beta. or BMP are allogeneic with respect to
the host recipient.
29. The method according to claim 20, wherein the first population
of fibroblast or chondrocyte cells transfected or transduced with
the gene encoding TGF-.beta. or BMP and the second population of
fibroblast or chondrocyte cells not transfected or transduced with
a gene encoding TGF-.beta. or BMP are xenogeneic with respect to
the host recipient.
30. The method of claim 20, wherein said recombinant vector is a
viral vector.
31. The method of claim 20, wherein said recombinant vector is a
plasmid vector.
32. The method of claim 20, wherein said cells are stored prior to
transplantation.
33. The method of claim 32, wherein said cells are stored in a
cryopreservative prior to transplantation.
34. The method of claim 20, wherein said transfection or
transduction is accomplished by liposome encapsulation, calcium
phosphate coprecipitation, electroporation, DEAE-dextran mediation
or virus mediation.
35. A method of treating osteoarthritis comprising: a) generating a
recombinant vector comprising a DNA sequence encoding transforming
growth factor .beta. (TGF-.beta.) or bone morphogenic protein (BMP)
operatively linked to a promoter; b) transfecting or transducing a
population of fibroblast or chondrocyte cells in vitro with said
recombinant vector; and c) injecting an injectable mixed cell
composition comprising hyaline cartilage-generating and
osteoarthritis treating effective amount of, (i) a first population
of fibroblast or chondrocyte cells transfected or transduced with a
gene encoding TGF-.beta. or BMP; (ii) a second population of
fibroblast or chondrocyte cells that have not been transfected or
transduced with a gene encoding TGF-.beta. or BMP; and (iii) a
pharmaceutically acceptable carrier thereof that is not a
non-living three dimensional structure into a joint space of a
mammal such that expression of the DNA sequence encoding TGF-.beta.
or BMP within the joint space occurs resulting in the generation of
bone and cartilage tissue in the joint space.
36-38. (canceled)
Description
CROSS-REFERENCE TO RELATED APPLICATION
[0001] The present application is a continuation application of
U.S. patent application Ser. No. 11/869,640, filed Oct. 9, 2007
(pending), which is a continuation application of U.S. patent
application Ser. No. 11/303,547, filed Dec. 16, 2005 (now U.S. Pat.
No. 7,282,200), which is a continuation application of U.S. patent
application Ser. No. 10/382,137, filed Mar. 5, 2003 (now U.S. Pat.
No. 7,005,127), the contents of which are incorporated by reference
herein in their entirety.
BACKGROUND OF THE INVENTION
[0002] 1. Field of the Invention
[0003] The present invention relates to using a mixture of cells
for somatic cell gene therapy. The present invention also relates
to a mixture of cells that include connective tissue cells
transfected or transduced with a gene encoding a member of the
transforming growth factor .beta. superfamily and connective tissue
cells that have not been transfected or transduced with a gene
encoding a member of the transforming growth factor .beta.
superfamily. The present invention also relates to a method of
regenerating cartilage by injecting the cell mixture to a mammalian
connective tissue. In addition, the present invention relates to a
method of treating osteoarthritis by injecting the cell mixture to
a mammalian connective tissue.
[0004] 2. Brief Description of the Related Art
[0005] In the orthopedic field, degenerative arthritis or
osteoarthritis is the most frequently encountered disease
associated with cartilage damage. Almost every joint in the body,
such as the knee, the hip, the shoulder, and even the wrist, is
affected. The pathogenesis of this disease is the degeneration of
hyaline articular cartilage (Mankin et al., J Bone Joint Surg, 52A:
460-466, 1982). The hyaline cartilage of the joint becomes
deformed, fibrillated, and eventually excavated. If the degenerated
cartilage could somehow be regenerated, most patients would be able
to enjoy their lives without debilitating pain.
[0006] Traditional routes of drug delivery, such as oral,
intravenous or intramuscular administration, to carry the drug to
the joint are inefficient. The half-life of drugs injected
intra-articularly is generally short. Another disadvantage of
intra-articular injection of drugs is that frequent repeated
injections are necessary to obtain acceptable drug levels at the
joint spaces for treating a chronic condition such as arthritis.
Because therapeutic agents heretofore could not be selectively
targeted to joints, it was necessary to expose the mammalian host
to systemically high concentrations of drugs in order to achieve a
sustained, intra-articular therapeutic dose. Exposure of non-target
organs in this manner exacerbated the tendency of anti-arthritis
drugs to produce serious side effects, such as gastrointestinal
upset and changes in the hematological, cardiovascular, hepatic and
renal systems of the mammalian host.
[0007] In the orthopedic field, some cytokines have been considered
as candidates for the treatment of orthopedic diseases. Bone
morphogenic protein has been considered to be an effective
stimulator of bone formation (Ozkaynak et al., EMBO J, 9:2085-2093,
1990; Sampath and Rueger, Complications in Ortho, 101-107, 1994),
and TGF-.beta. has been reported as a stimulator of osteogenesis
and chondrogenesis (Joyce et al., J Cell Biology, 110:2195-2207,
1990).
[0008] Transforming growth factor-.beta. (TGF-.beta.) is considered
to be a multifunctional cytokine (Sporn and Roberts, Nature
(London), 332: 217-219, 1988), and plays a regulatory role in
cellular growth, differentiation and extracellular matrix protein
synthesis (Madri et al., J Cell Biology, 106: 1375-1384, 1988).
TGF-.beta. inhibits the growth of epithelial cells and
osteoclast-like cells in vitro (Chenu et al., Proc Natl Acad Sci,
85: 5683-5687, 1988), but it stimulates enchondral ossification and
eventually bone formation in vivo (Critchlow et al., Bone, 521-527,
1995; Lind et al., A Orthop Scand, 64(5): 553-556, 1993; and
Matsumoto et al., In vivo, 8: 215-220, 1994). TGF-.beta.-induced
bone formation is mediated by its stimulation of the subperiosteal
pluripotential cells, which eventually differentiate into
cartilage-forming cells (Joyce et al., J Cell Biology, 110:
2195-2207, 1990; and Miettinen et al., J Cell Biology, 127-6:
2021-2036, 1994).
[0009] The biological effect of TGF-.beta. in orthopedics has been
reported (Andrew et al., Calcif Tissue In. 52: 74-78, 1993; Borque
et al., Int J Dev Biol., 37:573-579, 1993; Carrington et al., J
Cell Biology, 107:1969-1975, 1988; Lind et al., A Orthop Scand.
64(5):553-556, 1993; Matsumoto et al., In vivo, 8:215-220, 1994).
In mouse embryos, staining shows that TGF-.beta. is closely
associated with tissues derived from the mesenchyme, such as
connective tissue, cartilage and bone. In addition to embryologic
findings, TGF-.beta. is present at the site of bone formation and
cartilage formation. It can also enhance fracture healing in rabbit
tibiae. Recently, the therapeutic value of TGF-.beta. has been
reported (Critchlow et al., Bone, 521-527, 1995; and Lind et al., A
Orthop Scand, 64(5): 553-556, 1993), but its short-term effects and
high cost have limited wide clinical application.
[0010] Intraarticular injection of TGF-.beta. for the treatment of
arthritis is not desirable, because the injected TGF-.beta. has a
short duration of action, as TGF-.beta. is degraded into inactive
form in vivo. Therefore, a new method for long-term release of
TGF-.beta. is necessary for the regeneration of hyaline
cartilage.
[0011] There have been reports of regeneration of articular
cartilage with autotransplantation of cartilage cells (Brittberg et
al., New Engl J Med 331: 889-895, 1994), but this procedure entails
two operations with wide excision of soft tissues. If
intraarticular injection is enough for the treatment of
degenerative arthritis, it will be of great economic and physical
benefit to the patients.
[0012] Gene therapy, which is a method of transferring a specific
protein to a specific site, may be the answer to this problem
(Wolff and Lederberg, Gene Therapeutics ed. Jon A. Wolff, 3-25,
1994; and Jenks, J Natl Cancer Inst, 89(16): 1182-1184, 1997).
[0013] U.S. Pat. Nos. 5,858,355 and 5,766,585 disclose making a
viral or plasmid construct of the IRAP (interleukin-1 receptor
antagonist protein) gene; transfecting synovial cells (5,858,355)
and bone marrow cells (5,766,585) with the construct; and injecting
the transfected cells into a rabbit joint, but there is no
disclosure of using a gene belonging to the TGF-.beta. superfamily
to regenerate connective tissue.
[0014] U.S. Pat. Nos. 5,846,931 and 5,700,774 disclose injecting a
composition that includes a bone morphogenesis protein (BMP), which
belongs to the TGF .beta. "superfamily", together with a truncated
parathyroid hormone related peptide to effect the maintenance of
cartilaginous tissue formation, and induction of cartilaginous
tissue. However, there is no disclosure of a gene therapy method
using the BMP gene.
[0015] U.S. Pat. No. 5,842,477 discloses implanting a combination
of a scaffolding, periosteal/perichondrial tissue, and stromal
cells, including chondrocytes, to a cartilage defected area. Since
this patent disclosure requires that all three of these elements be
present in the implanted system, the reference fails to disclose or
suggest the simple gene therapy method of the invention which does
not require the implantation of the scaffolding or the
periosteal/perichondrial tissue.
[0016] U.S. Pat. No. 6,315,992 discloses that hyaline cartilage is
generated in defected mammalian joint when fibroblast cells
transfected with TGF-.beta.1 are injected into the defected knee
joint. However, the patent does not disclose the advantages of
using a mixed cell composition as in the present invention.
[0017] Lee et al. Human Gene Therapy, 12: 1085-1813, 2001 discloses
that hyaline cartilage is generated in defected mammalian joint
when fibroblast cells transfected with TGF-.beta.1 are injected
into the defected knee joint. However, Lee et al. does not disclose
using a mixed cell composition as in the present invention.
[0018] In spite of these prior art disclosures, there remains a
very real and substantial need for a more effective and potent
treatment method to not only regenerate connective tissue in the
mammalian host, but also better and more effective somatic cell
gene therapy methods as well.
SUMMARY OF THE INVENTION
[0019] The present invention has met the herein before described
need.
[0020] The presently claimed invention is directed to a mixed cell
composition that is used to generate a therapeutic protein at a
target site, comprising: a) a first population of mammalian cells
transfected or transduced with a gene that is sought to be
expressed; b) a second population of mammalian cells that have not
been transfected or transduced with the gene, wherein endogenously
existing forms of the second population of mammalian cells are
decreased at the target site, and wherein generation of the
therapeutic protein by the first population of mammalian cells at
the target site stimulates the second population cells to induce a
therapeutic effect; and c) a pharmaceutically acceptable carrier
thereof.
[0021] In the claimed invention, the mixed cell composition may be
in an injectable composition.
[0022] The claimed invention is further directed to a mixed cell
composition that includes a hyaline cartilage-generating effective
amount of: a) a first population of fibroblast or chondrocyte cells
transfected or transduced with a gene encoding transforming growth
factor .beta. (TGF-.beta.) or bone morphogenetic protein (BMP); b)
a second population of fibroblast or chondrocyte cells that have
not been transfected or transduced with a gene encoding TGF-.beta.
or BMP; and c) a pharmaceutically acceptable carrier thereof.
[0023] In a more specific embodiment, the claimed invention is
directed to a mixed cell composition that comprises hyaline
cartilage-generating effective amount of: a) a first population of
fibroblast cells transfected or transduced with a gene encoding
TGF-.beta. or BMP; b) a second population of chondrocyte cells that
have not been transfected or transduced with a gene encoding
TGF-.beta. or BMP; and c) a pharmaceutically acceptable carrier
thereof.
[0024] In the composition above, the composition may comprise a
hyaline cartilage-generating effective amount of: a) a first
population of chondrocyte cells transfected or transduced with a
gene encoding TGF-.beta. or BMP; b) a second population of
chondrocyte cells that have not been transfected or transduced with
a gene encoding TGF-.beta. or BMP; and c) a pharmaceutically
acceptable carrier thereof.
[0025] In the composition above, the gene may be, but not limited
to, TGF-.beta.1, TGF-.beta.2, TGF-.beta.3, BMP-2, BMP-3, BMP-4,
BMP-5, BMP-6, BMP-7 or BMP-9. In particular, the gene may be
TGF-.beta.1 or BMP-2.
[0026] Furthermore, in the composition, the ratio of the second
population of fibroblast or chondrocyte cells that have not been
transfected or transduced with a gene encoding TGF-.beta. or BMP to
the first population of fibroblast or chondrocyte cells that have
been transfected or transduced with a gene encoding TGF-.beta. or
BMP is from about 1-20 to 1. In particular, ratio may be from about
1-10 to 1, and further, about 1-3 to 1.
[0027] In the composition above, the first population of cells
transfected or transduced with a gene may be irradiated. And in
particular, the first population of fibroblast or chondrocyte cells
transfected or transduced with a gene encoding TGF-.beta. or BMP is
irradiated.
[0028] The cells of the mixed population of cells may be derived
from the same source organism. In particular, in certain
embodiments, the first population of fibroblast or chondrocyte
cells transfected or transduced with a gene encoding TGF-.beta. or
BMP and the second population of fibroblast or chondrocyte cells
not transfected or transduced with a gene encoding TGF-.beta. or
BMP are derived from the same source organism.
[0029] The cells of the mixed population of cells may be derived
from different source organisms. In particular, in certain
embodiments, the first population of fibroblast or chondrocyte
cells transfected or transduced with a gene encoding TGF-.beta. or
BMP and the second population of fibroblast or chondrocyte cells
not transfected or transduced with a gene encoding TGF-.beta. or
BMP are derived from different source organisms. The first
population of cells and the second population of cells may be
derived from different source mammals. And in particular, the first
population of fibroblast or chondrocyte cells transfected or
transduced with a gene encoding TGF-.beta. or BMP and the second
population of fibroblast or chondrocyte cells not transfected or
transduced with a gene encoding TGF-.beta. or BMP are derived from
different source mammals.
[0030] The presently claimed invention is also directed to a method
of generating a therapeutic protein at a target site in a mammal
comprising: a) generating a recombinant vector comprising a DNA
sequence encoding the therapeutic protein operatively linked to a
promoter; b) transfecting or transducing a population of cells in
vitro with said recombinant vector; and c) injecting a mixed cell
composition comprising protein generating effective amount of (i) a
first population of cells transfected or transduced with the gene;
(ii) a second population of cells that have not been transfected or
transduced with the gene; and (iii) a pharmaceutically acceptable
carrier thereof, into the target site, wherein endogenously
existing forms of the second population of mammalian cells are
decreased at the target site, and wherein generation of the
therapeutic protein by the first population of mammalian cells at
the target site stimulates the second population cells to induce a
therapeutic effect.
[0031] In particular, according to the above method, a method is
provided for generating hyaline cartilage in a mammal comprising:
a) generating a recombinant vector comprising a DNA sequence
encoding transforming growth factor .beta. (TGF-.beta.) or bone
morphogenic protein (BMP) operatively linked to a promoter; b)
transfecting or transducing a population of fibroblast or
chondrocyte cells in vitro with said recombinant vector; and c)
injecting an injectable mixed cell composition comprising hyaline
cartilage-generating effective amount of (i) a first population of
fibroblast or chondrocyte cells transfected or transduced with a
gene encoding TGF-.beta. or BMP; (ii) a second population of
fibroblast or chondrocyte cells that have not been transfected or
transduced with a gene encoding TGF-.beta. or BMP; and (iii) a
pharmaceutically acceptable carrier thereof, into a joint space of
a mammal such that expression of the DNA sequence encoding
TGF-.beta. or BMP within the joint space occurs resulting in the
generation of hyaline cartilage in the joint space.
[0032] According to the above method, the gene may be, but not
limited to, TGF-.beta.1, TGF-.beta.2, TGF-.beta.3, BMP-2, BMP-3,
BMP-4, BMP-5, BMP-6, or BMP-7. In particular, the gene may be
TGF-.beta.1 or BMP-2.
[0033] Furthermore, the method may encompass mixing the cells in a
ratio according to the following: the second population of
fibroblast or chondrocyte cells that have not been transfected or
transduced with a gene encoding TGF-.beta. or BMP to the first
population of fibroblast or chondrocyte cells that have been
transfected or transduced with a gene encoding TGF-.beta. or BMP
may be from about 3-20 to 1. The ratio may be from about 3-10 to 1.
Still further, the ratio may be from about 10 to 1.
[0034] The claimed invention also provides that in the above
method, the first population of fibroblast or chondrocyte cells
transfected or transduced with a gene encoding TGF-.beta. or BMP is
irradiated.
[0035] With regard to the source of the cells in the method
described above, the first population of fibroblast or chondrocyte
cells transfected or transduced with the gene encoding TGF-.beta.
or BMP and the second population of fibroblast or chondrocyte cells
not transfected or transduced with a gene encoding TGF-.beta. or
BMP are syngeneic, allogeneic, or xenogeneic with respect to the
host recipient.
[0036] The method described above may use a recombinant vector such
as a viral vector. The recombinant vector may be, but not limited
to, a plasmid vector. In addition, the transfection or transduction
may be accomplished by liposome encapsulation, calcium phosphate
coprecipitation, electroporation, DEAE-dextran mediation or virus
mediation.
[0037] In the practice of the claimed invention, cells may be
stored prior to transplantation. And the cells may be stored in a
cryopreservative prior to transplantation.
[0038] In another embodiment, the present invention is directed to
a method of treating osteoarthritis comprising: a) generating a
recombinant vector comprising a DNA sequence encoding transforming
growth factor .beta. (TGF-.beta.) or bone morphogenic protein (BMP)
operatively linked to a promoter; b) transfecting or transducing a
population of fibroblast or chondrocyte cells in vitro with said
recombinant vector; and c) injecting an injectable mixed cell
composition comprising hyaline cartilage-generating and
osteoarthritis treating effective amount of, (i) a first population
of fibroblast or chondrocyte cells transfected or transduced with a
gene encoding TGF-.beta. or BMP; (ii) a second population of
fibroblast or chondrocyte cells that have not been transfected or
transduced with a gene encoding TGF-.beta. or BMP; and (iii) a
pharmaceutically acceptable carrier thereof that is not a
non-living three dimensional structure into a joint space of a
mammal such that expression of the DNA sequence encoding TGF-.beta.
or BMP within the joint space occurs resulting in the generation of
bone and cartilage tissue in the joint space.
[0039] The present invention is further directed to an injectable
mixed cell composition comprising hyaline cartilage-generating
effective and osteoarthritis treating amount of: a) a first
population of fibroblast or chondrocyte cells transfected or
transduced with a gene encoding transforming growth factor .beta.
(TGF-.beta.) or bone morphogenic protein (BMP); b) a second
population of fibroblast or chondrocyte cells that have not been
transfected or transduced with a gene encoding TGF-.beta. or BMP;
and c) a pharmaceutically acceptable carrier thereof.
[0040] In a another embodiment of the claimed invention, the
presently claimed invention provides for a storage container for
storing cells at a temperature of about -70.degree. C. to about
-196.degree. C., comprising a mixed cell composition to generate a
protein at a site of interest, comprising: a) a first population of
mammalian cells transfected or transduced with a gene that is
sought to be expressed; b) a second population of mammalian cells
that have not been transfected or transduced with the gene, wherein
endogenously existing forms of the second population of mammalian
cells are decreased at the target site, and wherein generation of
the therapeutic protein by the first population of mammalian cells
at the target site stimulates the second population cells to induce
a therapeutic effect; and c) a pharmaceutically acceptable carrier
thereof.
[0041] In particular, the present application provides for a
storage container for storing cells at a temperature of about
-70.degree. C. to about -196.degree. C., comprising an injectable
mixed cell composition comprising hyaline cartilage-generating
effective amount of: a) a population of fibroblast or chondrocyte
cells transfected or transduced with a gene encoding TGF-.beta. or
BMP; b) a population of fibroblast or chondrocyte cells that have
not been transfected or transduced with a gene encoding TGF-.beta.
or BMP; and c) a pharmaceutically acceptable carrier thereof.
[0042] These and other objects of the invention will be more fully
understood from the following description of the invention, the
referenced drawings attached hereto and the claims appended
hereto.
BRIEF DESCRIPTION OF THE DRAWINGS
[0043] The present invention will become more fully understood from
the detailed description given herein below, and the accompanying
drawings which are given by way of illustration only, and thus are
not limitative of the present invention, and wherein;
[0044] FIG. 1 shows expression of TGF-.beta.1 mRNA. Total RNA was
isolated from NIH 3T3 cells or NIH 3T3 cells stably transfected
with pmT.beta.1, a TGF-.beta.1 expression vector, which were grown
in the absence or presence of zinc. Total RNA (15 mg) was probed
with either the TGF-.beta.1 cDNA or .beta. actin cDNA as a
control.
[0045] FIGS. 2A and 2B show expression of BMP2 in NIH3T3-BMP2
cells. FIGS. 2A and 2B show control NIH3T3-methallothionein (A) and
NIH3T3-BMP2 cells (B). Blue color in panel (B) shows expression of
BMP2 protein.
[0046] FIGS. 3A-3D show regeneration of cartilage with mixed-cell
(human chondrocytes and NIH3T3-TGF-.beta.1 cells) injection in
rabbits with a partial defect. FIGS. 3A and 3C show pictures of the
femoral condyles 6 weeks post injection with either a mixture of
hChon (human chondrocytes) and NIH3T3-TGF-.beta.1 cells (A) or
hChon alone (C). FIGS. 3B and 3D show Mason's trichrome staining of
sections from the femoral condyle injected with either a mixture of
hChon and NIH3T3-TGF-.beta.1 cells (B) or hChon alone (D). Original
magnification: (B & D) .times.12.5].
[0047] FIGS. 4A-4E show regeneration of cartilage with mixed-cell
(human chondrocytes and NIH3T3-TGF-.beta.1 cells) injection in
rabbits with a full-thickness defect. FIGS. 4A and 4D show pictures
of the femoral condyles 12 weeks post injection with either a
mixture of hChon and NIH3T3-TGF-.beta.1 cells (A) or hChon alone
(D). FIGS. 4B and 4E show Mason's trichrome staining, and FIG. 4C
shows Safranin-O staining of sections from the femoral condyle
injected with either a mixture of hChon and NIH3T3-TGF-.beta.1
cells (B & C) or hChon alone (E). Original magnification: (B, C
& E) .times.12.5.
[0048] FIGS. 5A-5D show regeneration of cartilage with mixed-cell
(human chondrocytes and NIH3T3-BMP-2 cells) injection in rabbits
with a partial defect. FIGS. 5A and 5C show pictures of the femoral
condyles 6 weeks post injection with either a mixture of hChon and
NIH3T3-BMP-2 cells (A) or hChon alone (C). FIGS. 5B and 5D show
Mason's trichrome staining of sections from the femoral condyle
injected with either a mixture of hChon and NIH3T3-BMP-2 cells (B)
or hChon alone (D). Original magnification: (B & D)
.times.12.5.
[0049] FIGS. 6A-6E show regeneration of cartilage with mixed-cell
(human chondrocytes and NIH3T3-BMP-2 cells) injection in rabbits
with a full-thickness defect. FIGS. 6A and 6D show pictures of the
femoral condyles 12 weeks post injection with either a mixture of
hChon and NIH3T3-BMP-2 cells (A) or hChon alone (D). FIGS. 6B and
6E show Mason's trichrome staining and FIG. 6C shows Safranin-O
staining of sections from the femoral condyle injected with either
mixture of hChon and NIH3T3-BMP-2 cells (B & C) or hChon alone
(E). Original magnification: (B, C & E) .times.12.5.
[0050] FIGS. 7A-7D show regeneration of cartilage with mixed-cell
(human chondrocytes and human chondrocyte-TGF-.beta.1 cells)
injection in rabbits with a full-thickness defect. FIGS. 7A and 7C
show pictures of the femoral condyles 6 weeks post injection with
either a mixture of hChon and hChon-TGF-.beta.1 cells (A) or hChon
alone (C). FIGS. 7B and 7D show Mason's trichrome staining of
sections from the femoral condyle injected with either mixture of
hChon and hChon-TGF-.beta.1 cells (B) or hChon alone (D). [Original
magnification: (B& D) .times.12.5].
[0051] FIGS. 8A-8D show regeneration of cartilage with mixed-cell
(human chondrocytes and human chondrocyte-TGF-.beta.1 Cells)
injection in rabbits with a partial defect. FIGS. 8A and 8C show
pictures of the femoral condyles 6 weeks post injection with a
mixture of hChon and hChon-TGF-.beta.1 cells (3:1 ratio) (A) or a
mixture of hChon and hChon-TGF-.beta.1 cells (5:1 ratio) (C). FIGS.
8B and 8D show Mason's trichrome staining of sections from the
femoral condyle injected with a mixture of hChon and
hChon-TGF-.beta.1 cells with 3:1 ratio (B) or 5:1 (D). [Original
magnification: (B& D) .times.12.5].
DETAILED DESCRIPTION OF THE INVENTION
[0052] As used herein, the term "patient" includes members of the
animal kingdom including but not limited to human beings.
[0053] As used herein, the term "mammalian host" includes members
of the animal kingdom including but not limited to human
beings.
[0054] As used herein, the term "connective tissue" is any tissue
that connects and supports other tissues or organs, and includes
but is not limited to a ligament, a cartilage, a tendon, a bone,
and a synovium of a mammalian host.
[0055] As used herein, the terms "connective tissue cell" and "cell
of a connective tissue" include cells that are found in the
connective tissue, such as fibroblasts, cartilage cells
(chondrocytes), and bone cells (osteoblasts/osteocytes), which
secrete collagenous extracellular matrix, as well as fat cells
(adipocytes) and smooth muscle cells. Preferably, the connective
tissue cells are fibroblasts, cartilage cells, and bone cells. It
will be recognized that the invention can be practiced with a mixed
culture of connective tissue cells, as well as cells of a single
type. It is also recognized that the tissue cells may be pretreated
with chemical compounds or radiation before injecting them into the
joint space so that the cells stably express the gene of interest
within the host organism. Preferably, the connective tissue cell
does not cause a negative immune response when injected into the
host organism. It is understood that allogeneic cells may be used
in this regard, as well as autologous cells for cell-mediated gene
therapy or somatic cell therapy.
[0056] As used herein, "connective tissue cell line" includes a
plurality of connective tissue cells originating from a common
parent cell.
[0057] As used herein, "decrease" of cells refers to a lessening of
a population of cells compared with the amount that would normally
be found at the site. This may mean a percentage reduction of a
population of cells, such as at least 10%, 20%, 30%, 40%, 50%, 60%,
70%, 80%, or 90% compared with the normal cell population at the
locus, or may mean damage or depletion of the cells at the
locus.
[0058] As used herein, "helper cells" refer to those cells that are
mixed with cells that are transfected or transduced with a gene of
interest. The helper cells themselves are not transfected or
transduced with the gene of interest. In particular, the cells
transfected or transduced with the gene of interest generate
protein that activates the helper cells. Administration of this
mixture to a site of interest where the helper cells are
endogenously made, but which are decreased at the time of
administration, results in advantageously effective somatic gene
therapy at the site of interest.
[0059] In one embodiment, "helper cells" may refer to connective
tissue cells transfected or transduced with a gene encoding a
member of the transforming growth factor .beta. superfamily to form
a mixture of cells. Such helper cells may include any connective
tissue cells. Generally, these cells are not transfected or
transduced with a gene encoding a member of the transforming growth
factor .beta. superfamily. In particular, these cells are not
transfected or transduced with any gene, and these cells are
generally resident in the cartilage area. Typically, the cell is a
fibroblast or a chondrocyte.
[0060] As used herein, "histocompatibility" of a donor cell and
recipient host refers to their sharing of a sufficient number of
histocompatibility agents so that a transplantation is accepted and
remains functional in the host mammal. In particular, the donor and
recipient pair should be matched for Human Leukocyte Antigens
(HLA), such as HLA type A, B, and C (Class I) and HLA type DR
(Class II).
[0061] As used herein, "hyaline cartilage" refers to the connective
tissue covering the joint surface. By way of example only, hyaline
cartilage includes, but is not limited to, articular cartilage,
costal cartilage, and nose cartilage.
[0062] In particular, hyaline cartilage is known to be
self-renewing, responds to alterations, and provides stable
movement with less friction. Hyaline cartilage found even within
the same joint or among joints varies in thickness, cell density,
matrix composition and mechanical properties, yet retains the same
general structure and function. Some of the functions of hyaline
cartilage include surprising stiffness to compression, resilience,
and exceptional ability to distribute weight loads, ability to
minimize peak stress on subchondral bone, and great durability.
[0063] Grossly and histologically, hyaline cartilage appears as a
slick, firm surface that resists deformation. The extracellular
matrix of the cartilage comprises chondrocytes, but lacks blood
vessels, lymphatic vessels or nerves. An elaborate, highly ordered
structure that maintains interaction between chondrocytes and the
matrix serves to maintain the structure and function of the hyaline
cartilage, while maintaining a low level of metabolic activity. The
reference O'Driscoll, J. Bone Joint Surg., 80A: 1795-1812, 1998
describes the structure and function of hyaline cartilage in
detail, which is incorporated herein by reference in its
entirety.
[0064] As used herein, "injectable" composition refers to a
composition that excludes various three-dimensional scaffold,
framework, mesh or felt structure, which may be made of any
material or shape that allows cells to attach to it and allows
cells to grow in more than one layer, and which structure is
generally implanted, and not injected. In one embodiment, the
injection method of the invention is typically carried out by a
syringe. However, any mode of injecting the composition of interest
may be used. For instance, catheters, sprayers, or temperature
dependent polymer gels also may be used.
[0065] As used herein, "mixed cell" or a "mixture of cells" or
"cell mixture" refers to the combination of a plurality of cells
that include a first population of cells that are transfected or
transduced with a gene of interest that is expressed to benefit the
helper cell, and which helper cells are the second population of
cells.
[0066] In one embodiment of the invention, mixed cells may refer to
the combination of a plurality of connective tissue cells that
include cells that have been transfected or transduced with a gene
or DNA encoding a member of the transforming growth factor .beta.
superfamily and helper cells that have not been transfected or
transduced with a gene encoding a member of the transforming growth
factor .beta. superfamily. Typically, the ratio of cells that have
not been transfected or transduced with a gene encoding a member of
the transforming growth factor .beta. superfamily to cells that
have been transfected or transduced with a TGF superfamily gene may
be in the range of about 3-20 to 1. The range may include about
3-10 to 1. In particular, the range may be about 10 to 1 in terms
of the number of cells. However, it is understood that the ratio of
these cells should not be necessarily fixed to any particular range
so long as the combination of these cells is effective to produce
hyaline cartilage in partially and fully defected joints.
[0067] As used herein, "pharmaceutically acceptable carrier" refers
to any carrier that is known in the art to promote the efficiency
of transport of the composition of the invention and prolong the
effectiveness of the composition.
[0068] As used herein, "somatic cell" or "cell" in general refers
to the cell of the body other than egg or sperm.
[0069] As used herein, "stored" cells refer to a composition of
mixed cells that have been either stored individually or together
before they are administered to the joint space. The cells may be
stored in a refrigeration unit. Alternatively, the cells may be
frozen at about -70.degree. to about -196.degree. C. in a liquid
nitrogen tank or in an equivalent storage unit so that the cells
are preserved for later administration into the joint space. The
cells may be thawed using known protocols. The duration of freezing
and thawing may be carried out by any number of ways, so long as
the viability and potency of the cells are optimized.
[0070] As used herein, the terms "transfection" and "transduction"
are mentioned as particular methods of transferring the DNA to the
host cell and its subsequent integration into the recipient cell's
chromosomal DNA. As the invention is practiced, any method
transferring a foreign DNA to a host cell may be used, including
nonviral or viral gene transfer methods, so long as a foreign gene
is introduced into the host cell and the foreign gene is stably
expressed in the host cell. Thus, as used herein, the term
"transfected or transduced" includes any method of gene delivery to
the cells, such as calcium phosphate precipitation, DEAE dextran,
electroporation, liposome, viral mediation and so on.
[0071] As used herein, the "transforming growth factor-.beta.
(TGF-.beta.) superfamily" encompasses a group of structurally
related proteins, which affect a wide range of differentiation
processes during embryonic development. The family includes,
Mullerian inhibiting substance (MIS), which is required for normal
male sex development (Behringer, et al., Nature, 345:167, 1990),
Drosophila decapentaplegic (DPP) gene product, which is required
for dorsal-ventral axis formation and morphogenesis of the imaginal
disks (Padgett, et al., Nature, 325:81-84, 1987), the Xenopus Vg-1
gene product, which localizes to the vegetal pole of eggs (Weeks,
et al., Cell, 51:861-867, 1987), the activins (Mason, et al.,
Biochem, Biophys. Res. Commun., 135:957-964, 1986), which can
induce the formation of mesoderm and anterior structures in Xenopus
embryos (Thomsen, et al., Cell, 63:485, 1990), and the bone
morphogenetic proteins (BMP's, such as BMP-2, 3, 4, 5, 6 and 7,
osteogenin, OP-1) which can induce de novo cartilage and bone
formation (Sampath, et al., J. Biol. Chem., 265:13198, 1990). The
TGF-.beta. gene products can influence a variety of differentiation
processes, including adipogenesis, myogenesis, chondrogenesis,
hematopoiesis, and epithelial cell differentiation. For a review,
see Massague, Cell 49:437, 1987, which is incorporated herein by
reference in its entirety.
[0072] The proteins of the TGF-.beta. family are initially
synthesized as a large precursor protein, which subsequently
undergoes proteolytic cleavage at a cluster of basic residues
approximately 110-140 amino acids from the C-terminus. The
C-terminal regions of the proteins are all structurally related and
the different family members can be classified into distinct
subgroups based on the extent of their homology. Although the
homologies within particular subgroups range from 70% to 90% amino
acid sequence identity, the homologies between subgroups are
significantly lower, generally ranging from only 20% to 50%. In
each case, the active species appears to be a disulfide-linked
dimer of C-terminal fragments. For most of the family members that
have been studied, the homodimeric species has been found to be
biologically active, but for other family members, like the
inhibins (Ung, et al., Nature, 321:779, 1986) and the TGF-.beta.'s
(Cheifetz, et al., Cell, 48:409, 1987), heterodimers have also been
detected, and these appear to have different biological properties
than the respective homodimers.
[0073] Members of the superfamily of TGF-.beta. genes include
TGF-.beta.3, TGF-.beta.2, TGF-.beta.4 (chicken), TGF-.beta.1,
TGF-.beta.5 (Xenopus), BMP-2, BMP-4, Drosophila DPP, BMP-5, BMP-6,
Vgr1, OP-1/BMP-7, Drosophila 60A, GDF-1, Xenopus Vgf, BMP-3,
Inhibin-(3A, Inhibin-.beta.B, Inhibin-.alpha., and MIS. These genes
are discussed in Massague, Ann. Rev. Biochem. 67:753-791, 1998,
which is incorporated herein by reference in its entirety.
[0074] Preferably, the member of the superfamily of TGF-.beta.
genes is TGF-.beta. and BMP. More preferably, the member is
TGF-.beta.1, TGF-.beta.2, TGF-.beta.3, BMP-2, BMP-3, BMP-4, BMP-5,
BMP-6, or BMP-7. Most preferably, the member is human or porcine
TGF-.beta.1 or BMP-2.
[0075] As used herein, "selectable marker" includes a gene product
that is expressed by a cell that stably maintains the introduced
DNA, and causes the cell to express an altered phenotype such as
morphological transformation, or an enzymatic activity. Isolation
of cells that express a transfected or transduced gene is achieved
by optional introduction into the same cells a second gene that
encodes a selectable marker, such as one having an enzymatic
activity that confers resistance to an antibiotic or other drug.
Examples of selectable markers include, but are not limited to,
thymidine kinase, dihydrofolate reductase, aminoglycoside
phosphotransferase, which confers resistance to aminoglycoside
antibiotics such as kanamycin, neomycin and geneticin, hygromycin B
phosphotransferase, xanthine-guanine phosphoribosyl transferase,
CAD (a single protein that possesses the first three enzymatic
activities of de novo uridine biosynthesis--carbamyl phosphate
synthetase, aspartate transcarbamylase and dihydroorotase),
adenosine deaminase, and asparagine synthetase (Sambrook et al.
Molecular Cloning, Chapter 16. 1989), incorporated herein by
reference in its entirety. It is understood that using a selectable
marker is not a requirement to practice the claimed invention. In
fact, in one embodiment, a selectable marker is not incorporated
into the genetic construct of the claimed invention.
[0076] As used herein, a "promoter" can be any sequence of DNA that
is active, and controls transcription in an eucaryotic cell. The
promoter may be active in either or both eucaryotic and procaryotic
cells. Preferably, the promoter is active in mammalian cells. The
promoter may be constitutively expressed or inducible. Preferably,
the promoter is inducible. Preferably, the promoter is inducible by
an external stimulus. More preferably, the promoter is inducible by
hormones or metals. Most preferably, the promoter is a
metallothionein gene promoter or a promoter inducible by
glucocorticoids. Likewise, "enhancer elements", which also control
transcription, can be inserted into the DNA vector construct, and
used with the construct of the present invention to enhance the
expression of the gene of interest.
[0077] As used herein, the term "DC-chol" means a cationic liposome
containing cationic cholesterol derivatives. The "DC-chol" molecule
includes a tertiary amino group, a medium length spacer arm (two
atoms) and a carbamoyl linker bond (Gao et al., Biochem. Biophys.
Res, Commun., 179:280-285, 1991).
[0078] As used herein, "SF-chol" is defined as a type of cationic
liposome.
[0079] As used herein, the term "biologically active" used in
relation to liposomes denotes the ability to introduce functional
DNA and/or proteins into the target cell.
[0080] As used herein, the term "biologically active" in reference
to a nucleic acid, protein, protein fragment or derivative thereof
is defined as an ability of the nucleic acid or amino acid sequence
to mimic a known biological function elicited by the wild type form
of the nucleic acid or protein.
[0081] As used herein, the term "maintenance", when used in the
context of liposome delivery, denotes the ability of the introduced
DNA to remain present in the cell. When used in other contexts, it
means the ability of targeted DNA to remain present in the targeted
cell or tissue so as to impart a therapeutic effect.
[0082] The present invention encompasses administering a mixture of
cells to a site in need thereof in a mammal, wherein the first
population of cells is transfected or transduced with a gene of
interest to be expressed at the site of interest in a mammal As
somatic gene therapy is attempted, the present invention provides
for including a second population of cells that are not transfected
or transduced with the gene of interest, and which cells are
endogenously decreased at the wounded or diseased or otherwise
debilitated site of interest, thus requiring activation by
expression of the gene of interest at the site of interest together
with the second population of cells to thus activate and grow the
cells of the second population type that are either endogenously
made or exogenously administered.
[0083] In particular, the present invention discloses ex vivo and
in vivo techniques for delivery of a DNA sequence of interest to
the connective tissue cells of the mammalian host. The ex vivo
technique involves culture of target connective tissue cells, in
vitro transfection or transduction of the DNA sequence, DNA vector
or other delivery vehicle of interest into the connective tissue
cells, followed by transplantation of the modified connective
tissue cells to the target joint of the mammalian host, so as to
effect in vivo expression of the gene product of interest.
[0084] It is to be understood that while it is possible that
substances such as a scaffolding or a framework as well as various
extraneous tissues may be implanted together in the gene therapy
protocol of the present invention, it is also possible that such
scaffolding or tissue not be included in the injection system of
the invention. In a preferred embodiment, in a cell-mediated gene
therapy or somatic cell therapy, the invention is directed to a
simple method of injecting a population of transfected or
transduced connective tissue cells to the joint space so that the
exogenous TGF superfamily protein is expressed in the joint
space.
[0085] One ex vivo method of treating a connective tissue disorder
disclosed throughout this specification comprises initially
generating a recombinant viral or plasmid vector which contains a
DNA sequence encoding a protein or biologically active fragment
thereof. This recombinant vector is then used to infect or
transfect a population of in vitro cultured connective tissue
cells, resulting in a population of connective cells containing the
vector. These connective tissue cells are then transplanted to a
target joint space of a mammalian host either as a mixture or
separately into the joint space so as to cause a mixture inside the
joint, thus effecting subsequent expression of the protein or
protein fragment within the joint space. Expression of this DNA
sequence of interest is useful in substantially reducing at least
one deleterious joint pathology associated with a connective tissue
disorder.
[0086] It will be understood by the artisan of ordinary skill that
the source of cells for treating a human patient may be the
patient's own connective tissue cells, such as autologous
fibroblast or chondrocyte cells, but that allogeneic cells as well
as xenogeneic cells may also be used without regard to the
histocompatibility of the cells. Alternatively, in one embodiment
of the invention, allogeneic cells may be used having matching
histocompatibility to the mammalian host. To describe in further
detail, the histocompatibility of the donor and the patient are
determined so that histocompatible cells are administered to the
mammalian host.
[0087] More specifically, this method includes employing as the
gene a gene capable of encoding a member of the transforming growth
factor .beta. superfamily, or a biologically active derivative or
fragment thereof and a selectable marker, or a biologically active
derivative or fragment thereof.
[0088] A further embodiment of the present invention includes
employing as the gene a gene capable of encoding at least one
member of the transforming growth factor .beta. superfamily or a
biologically active derivative or fragment thereof, and employing
as the DNA plasmid vector any DNA plasmid vector known to one of
ordinary skill in the art capable of stable maintenance within the
targeted cell or tissue upon delivery, regardless of the method of
delivery utilized.
[0089] Another embodiment of this invention provides a method for
introducing at least one gene encoding a product into at least one
cell of a connective tissue for use in treating the mammalian host.
This method includes employing non-viral means for introducing the
gene coding for the product into the connective tissue cell. More
specifically, this method includes a liposome encapsulation,
calcium phosphate coprecipitation, electroporation, or DEAE-dextran
mediation, and includes employing as the gene a gene capable of
encoding a member of transforming growth factor superfamily or
biologically active derivative or fragment thereof, and a
selectable marker, or biologically active derivative or fragment
thereof.
[0090] Another embodiment of this invention provides an additional
method for introducing at least one gene encoding a product into at
least one cell of a connective tissue for use in treating the
mammalian host. This additional method includes employing the
biologic means of utilizing a virus to deliver the DNA vector
molecule to the target cell or tissue. Preferably, the virus is a
pseudo-virus, the genome having been altered such that the
pseudovirus is capable only of delivery and stable maintenance
within the target cell, but not retaining an ability to replicate
within the target cell or tissue. The altered viral genome is
further manipulated by recombinant DNA techniques such that the
viral genome acts as a DNA vector molecule which contains the
heterologous gene of interest to be expressed within the target
cell or tissue.
[0091] A preferred embodiment of the invention is a method of
delivering TGF-.beta. or BMP to a target joint space by delivering
the TGF-.beta. or BMP gene to the connective tissue of a mammalian
host through use of a retroviral vector with the ex vivo technique
disclosed within this specification. In other words, a DNA sequence
of interest encoding a functional TGF-.beta. or BMP protein or
protein fragment is subcloned into a retroviral transfer vector of
choice. The recombinant retroviruses are produced in packaging
cells and then grown to adequate titer and used to infect in vitro
cultured connective tissue cells. The transduced connective tissue
cells, preferably autografted cells, are transplanted into the
joint of interest combined with a non-transfected or -transduced
sample of connective tissue cell such as chondrocytes preferably by
intra-articular injection.
[0092] Another preferred method of the present invention involves
direct in vivo delivery of a TGF-.beta. superfamily gene to the
connective tissue of a mammalian host through use of either a
retroviral vector, adenovirus vector, adeno-associated virus (AAV)
vector or herpes-simplex virus (HSV) vector. In other words, a DNA
sequence of interest encoding a functional TGF-.beta. or BMP
protein or protein fragment is subcloned into the respective viral
vector. The TGF-.beta. or BMP containing recombinant virus is then
grown to adequate titer and directed into the joint space,
preferably by intra-articular injection.
[0093] Methods of presenting the DNA molecule to the target
connective tissue of the joint includes, but is not limited to,
encapsulation of the DNA molecule into cationic liposomes,
subcloning the DNA sequence of interest in a retroviral or plasmid
vector, or the direct injection of the DNA molecule itself into the
joint. The DNA molecule, regardless of the form of presentation to
the knee joint, is preferably presented as a DNA vector molecule,
either as recombinant viral DNA vector molecule or a recombinant
DNA plasmid vector molecule. Expression of the heterologous gene of
interest is ensured by inserting a promoter fragment active in
eukaryotic cells directly upstream of the coding region of the
heterologous gene. One of ordinary skill in the art may utilize
known strategies and techniques of vector construction to ensure
appropriate levels of expression subsequent to entry of the DNA
molecule into the connective tissue.
[0094] In a preferred embodiment, fibroblasts and chondrocytes are
cultured in vitro for subsequent utilization as a delivery system
for gene therapy. It will be apparent that Applicants are not
limited to the use of the specific connective tissue disclosed. It
would be possible to utilize other tissue sources for in vitro
culture techniques. The method of using the gene of this invention
may be employed both prophylactically and in the therapeutic
treatment of osteoarthritis and wound healing. It will also be
apparent that the invention is not limited to prophylactic or
therapeutic applications for treating only the knee joint. It would
be possible to utilize the present invention either
prophylactically or therapeutically to treat osteoarthritis in any
susceptible joint or any damage resulting from an injury caused by
a tear or degradation of the cartilage.
[0095] In another embodiment of this invention, a compound for
parenteral administration to a patient in a therapeutically
effective amount is provided that contains a gene encoding a
TGF-.beta. superfamily protein and a suitable pharmaceutical
carrier.
[0096] Another embodiment of this invention provides for a compound
for parenteral administration to a patient in a prophylactically
effective amount that includes a gene encoding a TGF-.beta.
superfamily protein and a suitable pharmaceutical carrier.
[0097] In a further embodiment of this invention the cells are
stored before administration to the joint space. The transfected or
transduced cells alone may be stored, or the untransfected helper
cells alone may be stored, or the mixture may be stored, but not
necessarily simultaneously. In addition, the duration of storage
need not be for the same time period. Thus, the individually stored
cells may be mixed prior to injection. Alternatively, the cells may
be stored and injected separately to form a mixture of cells within
the joint space. It will be appreciated by those skilled in the art
that these cells may be stored frozen in a cryopreservative such as
but not limited to a composition of about 10 percent DMSO in liquid
nitrogen or an equivalent storage medium.
[0098] Another embodiment of this invention includes a method of
introducing at least one gene encoding a product into at least one
cell of a connective tissue of a mammalian host for use in treating
the mammalian host as hereinbefore described including effecting in
vivo the infection of the cell by introducing the viral vector
containing the gene encoding for the product directly into the
mammalian host. Preferably, this method includes effecting the
direct introduction into the mammalian host by intra-articular
injection. This method includes employing the method to
substantially prevent a development of arthritis in a mammalian
host having a high susceptibility of developing arthritis. This
method also includes employing the method on an arthritic mammalian
host for therapeutic use. Further, this method also includes
employing the method to repair and regenerate the connective tissue
as hereinbefore defined.
[0099] It will be appreciated by those skilled in the art, that the
viral vectors employing a liposome are not limited by cell division
as is required for the retroviruses to effect infection and
integration of connective tissue cells. This method employing
non-viral means as hereinbefore described includes employing as the
gene a gene capable of encoding a member belonging to the
TGF-.beta. superfamily and optionally with a selectable marker
gene, such as an antibiotic resistance gene. And it is also
understood that a selectable marker gene is not a requirement to
practicing the claimed invention.
[0100] Another embodiment of the present invention is delivery of a
DNA sequence encoding a member of the TGF-.beta. superfamily to the
connective tissue of a mammalian host by any of the methods
disclosed within this specification so as to effect in vivo
expression of collagen to regenerate connective tissue, such as
cartilage.
[0101] Connective tissues are difficult organs to target
therapeutically. Intravenous and oral routes of drug delivery that
are known in the art provide poor access to these connective
tissues and have the disadvantage of exposing the mammalian host
body systemically to the therapeutic agent. More specifically,
known intra-articular injection of proteins to joints provides
direct access to a joint. However, most of the injected drugs in
the form of encapsulated proteins have a short intra-articular
half-life. The present invention solves these problems by
introducing into the connective tissue of a mammalian host genes
coding for proteins that may be used to treat the mammalian host.
More specifically, this invention provides a method for introducing
into the connective tissue of a mammalian host genes coding for
proteins with anti-arthritic properties.
[0102] In the Examples provided herein, NIH3T3-TGF-.beta.1 and
NIH3T3-BMP-2 cells mixed with untransduced chondrocyte helper cells
stimulated collagen synthesis in the joint. In the Examples, the
joint was injected with 2.times.10.sup.6 cells/ml concentration of
a mixture of NIH3T3-TGF-.beta.1 or NIH3T3-BMP-2 cells and
untransduced chondrocyte helper cells at a 1:10 ratio of
transfected cells to helper cells. The specimens were harvested
from 6 weeks to 12 weeks after injection. The cells move freely
within the joint, and move to the area with specific affinity for
these cells. The synovium, meniscus and cartilage defect areas may
be possible sites for cellular adhesion. At six and twelve weeks
after injection, the regenerated tissues were observed in both the
partially and completely damaged cartilage defect areas. This
specific affinity for the damaged area is another advantage of
using mixed cells for clinical application. If degenerative
arthritis can be cured with just injection of cells into the joint
without including various physical apparatuses such as scaffolding
or any other three-dimensional structure, the patients can be
treated conveniently without major surgery.
[0103] Whatever the mechanism of action is, and without being bound
to any particular theory regarding the mechanism of action, the
finding of hyaline cartilage synthesis by using the mixed cell
composition of the invention indicates that a long duration of high
TGF-.beta. or BMP concentration can stimulate hyaline cartilage
regeneration. The properties of newly formed tissue were determined
by histological methods. Through Mason's trichrome staining and
Safranin-O, it was indicated that the newly formed tissue was
identical to the surrounding hyaline cartilage (FIGS. 3 through
7).
[0104] The following examples are offered by way of illustration of
the present invention, and not by way of limitation.
EXAMPLES
Example I--Materials and Methods
[0105] Plasmid Construction
[0106] The plasmid pMTMLV.beta.1 was generated by subcloning a
1.2-kb Bgl II fragment containing the TGF-.beta.1 coding sequence
and a growth hormone poly A site at the 3' end into the Bam HI site
of pMTMLV. The plasmid pMTBMP2 was generated by subcloning a 1.2-kb
Sal I-Not I fragment containing the BMP2 coding sequence into the
Sal I-Not I sites of pMTMLV. pMTMLV vector was derived from the
retroviral vector MFG by deleting entire gag and env sequences as
well as some of .PSI. packaging sequence.
[0107] Cell Culture and Transduction--The TGF-.beta. and BMP-2 cDNA
cloned in retroviral vectors were individually transduced into
fibroblasts (NIH3T3-TGF-.beta.1 and NIH3T3-BMP-2) and chondrocytes
(hChon-TGF-.beta.1). They were cultured in Dulbecco's Modified
Eagle's Medium (GIBCO-BRL, Rockville, Md.) with 10% concentration
of fetal bovine serum.
[0108] To select the cells with the transduced gene sequence,
neomycin (300 .mu.g/ml) was added into the medium. The cells with
TGF-.beta.1 and BMP-2 expression were sometimes stored in liquid
nitrogen and cultured just before the injection.
[0109] TGF-.beta. gene transfection was carried out by using the
calcium phosphate coprecipitation method (FIG. 1). About 80% of the
surviving colonies expressed the transgene mRNA. These selected
TGF-.beta.1-producing cells were incubated in a zinc sulfate
solution. When the cells were cultured in 100 mM zinc sulfate
solution, they produced mRNA. The TGF-.beta. secretion rate was
about 32 ng/10.sup.6 cells/24 hr.
[0110] To test and confirm the production of biologically active
BMP2 proteins by NIH3T3 fibroblast cells infected with retroviral
vectors containing BMP2 cDNAs, alkaline phosphatase (ALP) activity
assays were carried out with control NIH3T3-methallothionein (FIG.
2A) and NIH3T3-BMP2 cells (FIG. 2B). Blue color in FIG. 2B shows
expression of BMP2 protein.
[0111] 1.5.times.10.sup.6 NIH3T3 cells were grown overnight in a 6
well tissue culture plate. 0.5.times.10.sup.5 indicating cells
(MC3T3E1) were placed in tissue culture inserts and grown
overnight. Culture medium was aspirated from the culture insert and
the culture insert transferred into a 6 well plate and incubated
for 48-72 hours. Culture medium was aspirated from the culture
inserts. 5ml of 1.times. phosphate buffered saline (PBS) was added
to wash the cells. 4 ml of 3.7% formaldehyde/1.times. PBS solution
was added to each insert, and the cells were fixed for 20 min at
4.degree. C. Cells were washed twice with 1.times. PBS. 3 ml of ALP
staining solution was added to each culture insert, and the culture
insert was incubated for about 20 mM to 1 hr at room temperature in
the dark for blue color development. ALP staining solution is 0.1
mg/ml naphthol AS-MX phosphate (Sigma N5000), 0.5%,
N-dimethylformamide (Sigma D8654), 2 mM MgCl.sub.2, 0.3 mg/ml Fast
Blue BB salt (Sigma F3378) in 0.1 M Tris-HCl, pH 8.5.
Example II--Experimental Methods and Results
[0112] Regeneration of Rabbit Articular Cartilage Defect--New
Zealand white rabbits weighing 2.0-2.5 kg were selected for the
animal study. These rabbits were mature and had a tidemark. The
knee joint was exposed and a partial cartilage defect (3 mm.times.6
mm, 1-2 mm deep) or full-thickness defect (3 mm.times.6 mm, 2-3 mm
deep) was made on the hyaline cartilage layer of the femoral
condyle with a surgical knife. Either control human chondrocytes
(hChon), or mixture of hChon and NIH3T3-TGF-.beta.1 cells, or
NIH3T3-BMP-2 cells were injected into the rabbit knee joint with
the defect. These cells (15-20 .mu.l of 2.times.10.sup.6 cells/ml)
were loaded to the top of the defect and then left in the defect
for 15-20 min to allow the cells to permeate the wound before
suturing. In the experiment in which mixtures of hChon and
NIH3T3-BMP-2 cells were injected into rabbits with full-thickness
defect, these mixed cell compositions were injected into the defect
3 weeks after making the defect. The femoral condyles were
harvested at 6 or 12 weeks post injection of the cells and
examined.
[0113] Regeneration Of Cartilage With Mixed-Cell (Human
Chondrocytes And NIH3T3-TGF-.beta.1 Cells) Injection In Rabbits
With A Partial Defect--Either control hChon or a composition
comprising a mixture of hChon and NIH3T3-TGF-.beta.1 cells was
injected into the rabbit knee joint containing a partial cartilage
defect (3 mm.times.5 mm, 1-2 mm deep) on the femoral condyle. The
mixture of cells (15-20 .mu.l of 2.times.10.sup.6 cells/ml, 10:1
ratio of hChon and NIH3T3-TGF-.beta.1) was loaded to the top of the
defect and then left in the defect for 15-20 min to allow the cells
to permeate the wound before suturing. The specimens were harvested
at 6 weeks after injection and observed microscopically. FIGS. 3A
and 3C show pictures of the femoral condyles 6 weeks post injection
with either a mixture of hChon and NIH3T3-TGF-.beta.1 cells (A) or
hChon alone (C). FIGS. 3B and 3D show Mason's trichrome staining of
sections from the femoral condyle injected with either a mixture of
hChon and NIH3T3-TGF-.beta.1 cells (B) or hChon alone (D).
[Original magnification: (B & D) .times.12.5].
[0114] Regeneration Of Cartilage With Mixed-Cell (Human
Chondrocytes And NIH3T3-TGF-.beta.1 Cells) Injection In Rabbits
With A Full-Thickness Defect--Either control hChon or a mixture of
hChon and NIH3T3-TGF-.beta.1 cells was injected into the rabbit
knee joint containing a full-thickness cartilage defect (3
mm.times.5 mm, 2-3 mm deep) on the femoral condyle. The cell
mixture (20-25 .mu.l of 2.times.10.sup.6 cells/ml, 10:1 ratio of
hChon and NIH3T3-TGF-.beta.1) was loaded to the top of the defect
and then left in the defect for 15-20 min to allow the cells to
permeate the wound before suturing. The specimens were harvested at
12 weeks after injection and observed microscopically. FIGS. 4A and
4D show pictures of the femoral condyles 12 weeks post injection
with either a mixture of hChon and NIH3T3-TGF-.beta.1 cells (A) or
hChon alone (D). FIGS. 4B, 4C and 4E show Mason's trichrome
staining (B and E) and Safranin-O staining (C) of sections from the
femoral condyle injected with either mixture of hChon and
NIH3T3-TGF-.beta.1 cells (B and C) or hChon alone (E). [Original
magnification: (B, C & E) .times.12.5].
[0115] Regeneration Of Cartilage With Mixed-Cell (Human
Chondrocytes And NIH3T3-BMP-2 Cells) Injection In Rabbits With A
Partial Defect--Either control hChon or a mixture of hChon and
NIH3T3-BMP-2 cells were injected into the rabbit knee joint
containing a partial cartilage defect (3 mm.times.5 mm, 1-2 mm
deep) on the femoral condyle. The cell mixture (15-20 .mu.l of
2.times.10.sup.6 cells/ml, 10:1 ratio of hChon and NIH3T3-BMP-2)
was loaded to the top of the defect and then left in the defect for
15-20 min to allow the cells to permeate the wound before suturing.
The specimens were harvested at 6 weeks after injection and
observed microscopically. FIGS. 5A and 5C show pictures of the
femoral condyles 6 weeks post injection with either mixture of
hChon and NIH3T3-BMP-2 cells (A) or hChon alone (C). FIGS. 5B and
5D show Mason's trichrome staining of sections from the femoral
condyle injected with either mixture of hChon and NIH3T3-BMP-2
cells (B) or hChon alone (D). [Original magnification: (B and D)
.times.12.5].
[0116] Regeneration Of Cartilage With Mixed-Cell (Human
Chondrocytes And NIH3T3-BMP-2 Cells) Injection In Rabbits With A
Full-Thickness Defect--Either control hChon or a mixture of hChon
and NIH3T3-BMP-2 cells was injected into the rabbit knee joint
containing a full-thickness cartilage defect (3 mm.times.5 mm, 2-3
mm deep) on the femoral condyle. In this case, the cells were
injected 3 weeks after making the defect. The cell mixture (20-25
.mu.l of 2.times.10.sup.6 cells/ml, 10:1 ratio of hChon and
NIH3T3-BMP-2) was loaded to the top of the defect and then left in
the defect for 15-20 min to allow the cells to permeate the wound
before suturing. The specimens were harvested at 6 weeks after
injection and observed microscopically. FIGS. 6A and 6D show
pictures of the femoral condyles 12 weeks post injection with
either a mixture of hChon and NIH3T3-BMP-2 cells (A) or hChon alone
(D). FIGS. 6B, 6C and 6E show Mason's trichrome staining (B and E)
and Safranin-O staining (C) of sections from the femoral condyle
injected with either a mixture of hChon and NIH3T3-BMP-2 cells (B
and C) or hChon alone (E). [Original magnification: (B, C and E)
.times.12.5].
[0117] Regeneration Of Cartilage With Mixed-Cell (Human
Chondrocytes And Human Chondrocyte-TGF-.beta.1 Cells) Injection In
Rabbits With A Full-Thickness Defect--Either control human
chondrocytes (hChon) or a mixture of hChon and hChon-TGF-.beta.1
cells was injected into the rabbit knee joint containing a
full-thickness cartilage defect (3 mm.times.5 mm, 2-3 mm deep) on
the femoral condyle. The cell mixture (20-25 .mu.l of
2.times.10.sup.6 cells/ml, 1:1 ratio of hChon and
hChon-TGF-.beta.1) was loaded to the top of the defect and then
left in the defect for 15-20 min to allow the cells to permeate the
wound before suturing. The specimens were harvested at 6 weeks
after injection and observed microscopically. FIGS. 7A and 7C show
pictures of the femoral condyles 6 weeks post injection with either
a mixture of hChon and hChon-TGF-.beta.1 cells (A) or hChon alone
(C). FIGS. 7B and 7D show Mason's trichrome staining of sections
from the femoral condyle injected with either mixture of hChon and
hChon-TGF-.beta.1 cells (B) or hChon alone (D). [Original
magnification: (B& D) .times.12.5].
[0118] Regeneration Of Cartilage With Mixed-Cell (Human
Chondrocytes And Human Chondrocyte-TGF-.beta.1 Cells) Injection In
Rabbits With A Partial Defect--A mixture of hChon and
hChon-TGF-.beta.1 cells was injected into the rabbit knee joint
containing a partial cartilage defect (3 mm.times.5 mm, 1-2 mm
deep) on the femoral condyle. The cell mixture (15-20 .mu.l of
2.times.10.sup.6 cells/ml, 3:1 or 5:1 ratio of hChon and
hChon-TGF-.beta.1) was loaded to the top of the defect and then
left in the defect for 15-20 min to allow the cells to permeate the
wound before suturing. The specimens were harvested at 6 weeks
after injection and observed microscopically. FIGS. 8A and 8C show
pictures of the femoral condyles 6 weeks post injection with a
mixture of hChon and hChon-TGF-.beta.1 cells (3:1 ratio) (A) or a
mixture of hChon and hChon-TGF-.beta.1 cells (5:1 ratio) (C). FIGS.
8B and 8D show Mason's trichrome staining of sections from the
femoral condyle injected with a mixture of hChon and
hChon-TGF-.beta.1 cells with 3:1 ratio (B) or 5:1 (D). [Original
magnification: (B& D) .times.12.5].
[0119] All of the references cited herein are incorporated by
reference in their entirety.
[0120] Whereas particular embodiments of this invention have been
described above for purposes of illustration, it will be evident to
those persons skilled in the art that numerous variations of the
details of the present invention may be made without departing from
the invention as defined in the appended claims.
* * * * *